In 2016, the French market of reimbursed antidiabetic drugs valued 1.055 Euro billion in terms of manufacturers' revenue. The total diabetes drug related expenditure of the National Insurance has reached 1,32 Euro billion in 2016 (includes distribution margin and VAT). The National Insurance covers 99% of the French population; most of diabetic patients benefit from full coverage of the drug-associated costs. The number of French diabetic patients taking antidiabetic medications (i.e. reimbursed for any antidiabetic medication) has grown by 2.07% from 2014 to 2015 and by 1.54% from 2015 to 2016 reaching a total number of 3.587 million persons by the end of 2016.
Data sources: Open Medic and Medic'AM databases of the French National Health Insurance.
Used datasets 1
You can easily embed this reuse on your website by pasting this snippet in your html page.
Discussion between the organization and the community about this dataset.